23/08/2026
âA NEW MEDICINE FOR AUTISM IS COMING. WILL AUTISTIC CHILDREN NOW START SPEAKING?â
What the evidence actually says about L1-79
Over the past few days, a video making claims about a ânew medicine for autismâ has been widely shared on social media.
Many parents have contacted me personally. Similar questions have reached the Dignified Independence Global Help Line and our Cluster Coordinators:
âIs this true?â
âHas the medicine already been approved?â
âWill it cure autism?â
âCould it make my non-speaking child begin to speak?â
âWill it help every autistic child?â
I understand why this news has generated such powerful hope. When a family has spent years supporting a child with substantial communication or daily-living needs, even the suggestion of a new treatment can carry enormous emotional weight.
As a psychologist, and as Founder and Chief Coordinator of Dignified Independenceâan organisation supporting autistic people, persons with disabilities, and families across different levels of needâI felt a responsibility to examine the claim carefully.
This is particularly important to me because the Inclusive Adaptation framework asks society not merely to change the individual, but to adapt communication, education, technology, services, workplaces, and environments around the person.
I therefore reviewed the available clinical-trial records, regulatory information, company disclosures and published research. I was also able to communicate with representatives of Yamo Pharmaceuticals, the company developing L1-79.
Here is the evidence-based position as of 23 August 2026.
THE SHORT ANSWER
⢠Has a new medicine been approved to treat the core features of autism? No.
⢠Is L1-79 approved by the US FDA for autism? No.
⢠Is Phase 3 already underway? No. The company has announced plans to begin it in early 2027.
⢠Will L1-79 cure autism? No evidence supports that claim.
⢠Will it make a non-speaking child begin speaking? The existing study does not answer that question.
⢠Will it benefit every autistic person? We do not know, and the Phase 2 study cannot support such a conclusion.
⢠Is the research promising? Yesâbut âpromisingâ and âprovenâ are not the same thing.
AUTISM IS NOT AN ILLNESS THAT A TABLET SIMPLY REMOVES
Autism is a diverse, lifelong neurodevelopmental condition associated with differences in brain development, communication, social interaction, sensory processing, behaviour, interests and patterns of activity.
Autistic people have different strengths, challenges, preferences and support needs. Those needs may also change over time.
This does not mean that medical care is irrelevant. Autistic people may experience co-occurring conditions such as epilepsy, sleep difficulties, anxiety, ADHD, gastrointestinal problems or severe irritability that require appropriate assessment and treatment.
Individualised, evidence-informed support can also improve communication, well-being, daily functioning and independence.
However, treating a specific difficulty or improving a particular area of functioning is not the same as âcuring autismâ or removing an autistic personâs identity.
WHAT EXACTLY IS L1-79?
L1-79 is an investigational oral compound also known as racemetirosine or racemic alpha-methyl-p-tyrosine.
It inhibits tyrosine hydroxylase, the rate-limiting enzyme involved in producing catecholamines such as dopamine and norepinephrine.
Researchers are investigating whether modifying catecholamine signalling could improve certain aspects of social functioning and social communication in some autistic people.
That is a scientific hypothesis being tested. It is not yet an established treatment.
Yamo Pharmaceuticals reports that L1-79 received FDA Fast Track designation in 2018. This is worth noting, but Fast Track status is not FDA approval and does not prove that a medicine is safe or effective. It is a mechanism intended to facilitate the development and review of a potential treatment addressing an unmet medical need.
WHAT DID THE PHASE 2 STUDY ACTUALLY FIND?
The relevant Phase 2 study is registered as NCT05067582.
It enrolled 58 autistic adolescents and young adults between 12 and 21 years of age. It was a multicentre, randomised, double-blind, placebo-controlled, two-period crossover trial.
The participants were a selected group. Eligibility included a WASI-II score of at least 70 and a specified minimum level of socialisation-related difficulty. Therefore, the findings cannot automatically be generalised to younger children, people with intellectual disabilities, non-speaking children, or the entire autistic population.
According to results reported by Yamo Pharmaceuticals and presented at INSAR 2025, L1-79 showed a 7.94-point advantage over placebo on the Vineland-3 Socialization Standard Score during the first treatment period. The result was statistically significant, with a p-value of approximately 0.01.
The company also reported improvements on some clinician- and caregiver-rated measures and stated that no serious adverse events or withdrawals caused by side effects occurred among participants receiving L1-79.
These findings deserve serious scientific attention.
However, they must be interpreted correctly.
First, 7.94 points represents an average difference between the treatment and placebo groups. It does not mean that every participant improved by that amount.
Second, the Vineland Socialization score assesses areas such as interpersonal relationships, play and leisure, and coping skills. It is not a test showing that a non-speaking person acquired spoken language.
Third, because the results differed between the two study periodsâa statistically significant period-by-treatment interactionâthe company confined the main efficacy analysis to Period 1. That is important context when interpreting a crossover trial.
Fourth, these are currently company-reported and conference-presented results. As of 23 August 2026, detailed results had not been publicly posted in the ClinicalTrials.gov results database, and I could not identify a full peer-reviewed publication of this Phase 2 trial.
Finally, a study of 58 selected participants cannot establish long-term safety, effectiveness across the wider autistic population, or which subgroups may benefit.
Therefore, I would not say:
âThis medicine has been proven.â
I would say:
âAn encouraging Phase 2 signal has been reported, and it now requires independent scrutiny and confirmation in a larger Phase 3 programme.â
WILL MY NON-SPEAKING CHILD BEGIN TO SPEAK?
Based on the evidence currently available, the honest answer is:
We do not knowâand this study provides no evidence that L1-79 causes non-speaking children to acquire spoken language.
The study was not designed to answer that question. It did not specifically study a population of young non-speaking children, and the primary measure was socialisationânot the emergence of speech.
An improvement in socialisation or social engagement must not be translated into the claim that âspeech will come.â
Speech is also only one form of communication. Gestures, sign language, pictures, writing, communication devices and augmentative and alternative communicationâAACâare all valid forms of communication.
A child should never be denied an effective communication system while everyone waits to see whether spoken language develops.
WILL IT HELP EVERY AUTISTIC CHILD?
That cannot be claimed.
Autism is highly heterogeneous. A treatment that benefits one subgroup may have little effectâor unacceptable side effectsâin another.
The Phase 2 trial involved only people aged 12â21 who met specific eligibility criteria. It does not tell us how the medicine would affect:
⢠Young children
⢠Older adults
⢠People with intellectual disabilities
⢠People with very high support needs
⢠Non-speaking autistic people as a distinct group
⢠People with different medical or genetic profiles
⢠People using multiple medications
⢠People receiving the treatment for much longer periods
These are among the questions that future research must address.
WHY SHOULD WE WAIT FOR PHASE 3?
Autism research has seen promising early findings fail to hold up in larger trials before.
Balovaptan, developed by Roche, targeted the vasopressin V1a receptor and was intended to improve social communication. Early findings led the FDA to grant it Breakthrough Therapy designation in 2018.
However, its Phase 3 V1ADUCT trial in autistic adults was terminated for futility because it was considered highly unlikely to meet its primary objective. A separate randomised trial involving autistic children and adolescents also failed to demonstrate improvement in socialisation and communication.
Bumetanide provides another important example.
Based on a hypothesis involving neuronal chloride levels and GABA signalling, bumetanide was studied as a possible treatment for autism-related characteristics. Servier and Neurochlore conducted two large Phase 3 trials involving a total of 422 children and adolescents.
Both studies were terminated early because no statistically significant benefit over placebo was found on the primary or secondary efficacy outcomes. The sponsor subsequently discontinued that development programme for paediatric autism.
These examples do not prove that L1-79 will fail.
They demonstrate why a positive Phase 2 result must not be treated as a successful Phase 3 resultâor as regulatory approval.
WHAT HAPPENS NEXT?
Yamo Pharmaceuticals announced in June 2026 that it plans to begin Phase 3 trials in early 2027.
That is a planned trial starting dateânot a date when the medicine will become available to the public.
The company has stated that it must secure funding, establish trial sites and enrol participants. A large Phase 3 programme must then determine whether the reported benefit can be replicated, identify who may benefit, assess risks and side effects, and examine whether any improvement is meaningful and sustainable.
Even if Phase 3 succeeds, the complete evidence would still need to undergo regulatory review before any approval could be considered.
Therefore, claims that L1-79 âwill be available in 2027â are not supported by the current evidence.
WHAT SHOULD FAMILIES DO NOW?
Please do not change or discontinue a childâs current treatment, therapy, communication support or educational programme because of a social-media video.
Do not attempt to obtain L1-79âor another medicine believed to resemble itâand use it without legitimate clinical-trial supervision.
L1-79 remains investigational. Its safety and effectiveness have not yet been established for routine clinical use.
Any decision involving medication should be made with a qualified healthcare professional who understands the individualâs complete medical history, current medication, co-occurring conditions and specific needs.
Individualised and respectful supports remain important, including speech and language services, occupational support, AAC, educational and developmental interventions, sensory accommodations, family guidance, mental-health support and appropriate treatment of co-occurring medical conditions.
A future medication, even if successful, should be viewed as one possible toolânot as a replacement for every other form of support.
RESEARCH MUST NOT DELAY INCLUSION
We should continue supporting responsible medical research. At the same time, an autistic personâs dignity, communication rights and inclusion cannot be made conditional on a future medicine.
We must adapt communication systems, classrooms, workplaces, healthcare services, transportation, technology, community environments and public attitudes now.
The question should not be only:
âHow can we make this person fit the existing world?â
We must also ask:
âHow can we adapt the world so that this person can communicate, participate, live with dignity and exercise greater independence?â
That is the principle at the heart of Inclusive Adaptation.
MY CONCLUSION
Hope â yes.
Hype â no.
An autism cure â no.
A guarantee of speech â no.
A promising Phase 2 research signal â yes.
A proven treatment â not yet.
Phase 3 planned â yes.
Phase 3 completed â no.
FDA approval â no.
For many families, the wish for progress does not come from rejecting their child or searching for a miracle. It comes from wanting their child to experience less distress, communicate more effectively, have their needs understood, participate more fully and achieve the greatest possible independence.
A new word can be meaningful.
A new gesture can be meaningful.
A successful AAC request can be meaningful.
Reduced distress can be meaningful.
Being able to communicate pain, hunger, fear, preference or affection can be life-changing.
We can recognise the importance of these possibilities without turning preliminary research into a miracle-cure narrative.
Let us remain hopeful.
Let us continue asking questions.
Let us examine the evidence.
Let us protect families from misinformation and commercial exploitation.
And while research continues, let us love, respect, accommodate and include autistic people exactly as they are today.
If you have seen claims about L1-79, please share the original sourceânot only the headline. Let us examine the evidence together and ensure that accurate information reaches every family.
Dr Nawab Wajid
Psychologist
Founder & Chief Coordinator â Dignified Independence
Originator of Inclusive Adaptation
Sources reviewed: WHO; NIMH; US FDA; ClinicalTrials.gov records NCT05067582 and NCT02947048; Yamo Pharmaceuticals Phase 2 and Phase 3 announcements; published Phase 3 research on balovaptan and bumetanide.
This post is for public education and does not replace individual medical advice.
